Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0R3EL
|
||||
| Former ID |
DCL000372
|
||||
| Drug Name |
GSK184072
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Colon cancer; Hematologic cancers; Type 2 diabetes [ICD9: 140-229, 250, 250.00, 250.02; ICD10:E08-E13, E11] | Discontinued in Phase 2 | [1] | ||
| Company |
GSK
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C12H18N2O3
|
||||
| Canonical SMILES |
CC(C)CC1=NC(=CC(C)C)C(=O)N(C1=O)O
|
||||
| InChI |
1S/C12H18N2O3/c1-7(2)5-9-11(15)14(17)12(16)10(13-9)6-8(3)4/h5,7-8,17H,6H2,1-4H3/b9-5-
|
||||
| InChIKey |
SIXHCCPAJIVTOY-UITAMQMPSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | NAD-dependent deacetylase sirtuin-1 | Target Info | Activator | [2] | |
| KEGG Pathway | FoxO signaling pathway | ||||
| AMPK signaling pathway | |||||
| Glucagon signaling pathway | |||||
| Amphetamine addiction | |||||
| MicroRNAs in cancer | |||||
| PANTHER Pathway | p53 pathway | ||||
| Pathway Interaction Database | p73 transcription factor network | ||||
| Signaling events mediated by HDAC Class III | |||||
| E2F transcription factor network | |||||
| HIF-2-alpha transcription factor network | |||||
| Signaling events mediated by HDAC Class I | |||||
| FoxO family signaling | |||||
| Regulation of Androgen receptor activity | |||||
| Regulation of retinoblastoma protein | |||||
| Reactome | RORA activates gene expression | ||||
| Regulation of HSF1-mediated heat shock response | |||||
| Circadian Clock | |||||
| WikiPathways | Integrated Pancreatic Cancer Pathway | ||||
| SREBF and miR33 in cholesterol and lipid homeostasis | |||||
| Integrated Breast Cancer Pathway | |||||
| SREBP signalling | |||||
| Androgen receptor signaling pathway | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024569) | ||||
| REF 2 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.